Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
Cue Biopharma licensed the clinical-stage anti-IgE antibody Ascendant-221 from Ascendant Health Sciences, paying $15M upfront and committing up to $676.5M in milestones. The deal grants Cue global rights excluding Greater China, with plans to launch a Phase 2b food allergy trial after Phase 2 data in chronic spontaneous urticaria arrives in 2H 2026.
Key figures
- Drug Name
- Ascendant-221
- Phase Of Trial
- Phase 2
- Upfront payment
- $15 million
- Potential milestone payments
- $676.5 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.